^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ISM6466A

    i
    Other names: ISM6466A
    Associations

    News

    Trials
    Company:
    Insilico Medicine
    Drug class:
    CDK12 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Discovery and evaluation of ISM6466A, a novel covalent CDK12 inhibitor for the treatment of cancer (AACR 2023)
    Results from a 28-day rat DRF study revealed that the compound did not show evident signs of toxicity at the tested doses, suggesting a reasonable safety window for ISM6466A.In summary, the novel, covalent, small-molecule CDK12 inhibitor, ISM6466A, demonstrated excellent preclinical efficacy along with favorable drug-like properties. Our results underscore the therapeutic potential of ISM6466A for the treatment of cancer.
    BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    CDK12 mutation • BRCA1 expression
    |
    ISM6466A